Jury says Apple owes Masimo $634M for patent infringement | TechCrunch

Topics Latest AI Amazon Apps Biotech & Health Climate Cloud Computing Commerce Crypto Enterprise EVs Fintech Fundraising Gadgets Gaming Google Government & Policy Hardware Instagram Layoffs Media & Entertainment Meta Microsoft Privacy Robotics Security Social Space Startups TikTok Transportation Venture
Latest AI Amazon Apps Biotech & Health Climate Cloud Computing Commerce Crypto Enterprise EVs Fintech Fundraising Gadgets Gaming Google Government & Policy
Hardware Instagram Layoffs Media & Entertainment Meta Microsoft Privacy Robotics Security Social Space Startups TikTok Transportation Venture

More from TechCrunch Staff Events Startup Battlefield StrictlyVC Newsletters Podcasts Videos Partner Content TechCrunch Brand Studio Crunchboard Contact Us
A federal jury in California ruled Friday that Apple must pay medical device maker Masimo $634 million for infringing a patent on blood oxygen-monitoring technology.Reuters reports the jury found that the Apple Watch’s workout mode and heart rate notification features violated Masimo’s patent.“This is a significant win in our ongoing efforts to protect our innovations and intellectual property, which is crucial to our ability to develop technology that benefits patients,” Masimo said in a statement.

“We remain committed to defending our IP rights moving forward.” An Apple spokesperson said in a statement that the verdict is “contrary to the facts” and that Apple plans to appeal.“Masimo is a medical device company that does not sell any products to consumers,” the spokesperson said.“Over the past six years they have sued Apple in multiple courts and asserted over 25 patents, the majority of which have been found to be invalid.

The single patent in this case expired in 2022, and is specific to historic patient monitoring technology from decades ago.” The legal dispute between Masimo and Apple focuses on pulse oximetry, which uses an optical sensor to detect blood flow.Masimo has accused Apple of hiring away its employees — including its chief medical officer — and infringing its patents on pulse oximetry technology.  The U.S.International Trade Commission sided by Masimo in 2023, banning Apple from importing Apple Watches with blood oxygen-monitoring features — which is why Apple Watches have not supported blood oxygen monitoring in recent years.

Techcrunch event Join the Disrupt 2026 Waitlist Add yourself to the Disrupt 2026 waitlist to be first in line when Early Bird tickets drop.Past Disrupts have brought Google Cloud, Netflix, Microsoft, Box, Phia, a16z, ElevenLabs, Wayve, Hugging Face, Elad Gil, and Vinod Khosla to the stages — part of 250+ industry leaders driving 200+ sessions built to fuel your growth and sharpen your edge.Plus, meet the hundreds of startups innovating across every sector.

Join the Disrupt 2026 Waitlist Add yourself to the Disrupt 2026 waitlist to be first in line when Early Bird tickets drop.Past Disrupts have brought Google Cloud, Netflix, Microsoft, Box, Phia, a16z, ElevenLabs, Wayve, Hugging Face, Elad Gil, and Vinod Khosla to the stages — part of 250+ industry leaders driving 200+ sessions built to fuel your growth and sharpen your edge.Plus, meet the hundreds of startups innovating across every sector.

San Francisco | October 13-15, 2026 WAITLIST NOW Then Apple announced in August of this year that it’s introducing a new version of the feature designed to circumvent the ban, with blood oxygen readings measured and calculated on the user’s paired iPhone, rather than on the Apple Watch itself.Masimo is suing U.S.Customs and Border Protection for approving the import of Apple Watches with the new blood oxygen implementation, while Apple has asked an appeals court to overturn the import ban.

Apple also countersued Masimo, winning the statutory minimum payment of $250 when a jury found that Masimo had violated Apple design patents.This post has been updated with more details from Apple’s statement.Topics Apple, Apple Watch, Biotech & Health, Gadgets, Hardware, masimo, pulse oximetry Anthony Ha Anthony Ha is TechCrunch’s weekend editor.

Previously, he worked as a tech reporter at Adweek, a senior editor at VentureBeat, a local government reporter at the Hollister Free Lance, and vice president of content at a VC firm.He lives in New York City. You can contact or verify outreach from Anthony by emailing [email protected] Bio
X LinkedIn Facebook Instagram youTube Mastodon Threads Bluesky
TechCrunchStaffContact UsAdvertiseCrunchboard JobsSite Map Terms of ServicePrivacy PolicyRSS Terms of UseCode of Conduct AWS re:InventApple AIZillowClipbookNvidiaTech LayoffsChatGPT
TechCrunchStaffContact UsAdvertiseCrunchboard JobsSite Map
Terms of ServicePrivacy PolicyRSS Terms of UseCode of Conduct
AWS re:InventApple AIZillowClipbookNvidiaTech LayoffsChatGPT

Read More
Related Posts